Researchers identify link between pancreatic cancer-driving mutations
A study has shown that p53 rewires RNA splicing which leads to further activation of the KRAS oncogene, presenting a target for the progression of pancreatic cancer.
List view / Grid view
A study has shown that p53 rewires RNA splicing which leads to further activation of the KRAS oncogene, presenting a target for the progression of pancreatic cancer.
In lab conditions, a new biomaterial was able to accelerate bone regeneration by boosting an immune response that encourages repair.
Non-invasive imaging has played an increasing role in drug discovery and development processes. Nikki Withers spoke with Yochi Slonim, who discusses a novel technology that leverages FRET signals for the discovery of small molecule drugs that selectively control mRNA translation in a novel target space.
The articles in this in-depth focus discuss the difficulties in deciding what information to capture when imaging three-dimensional (3D) cell models and the use of non-invasive imaging techniques to discover small molecule drugs to control protein translation.
Post-infection genome editing could be the cause of mutations in the SARS-CoV-2 virus responsible for the COVID-19 pandemic, driving its evolution.
A MERS vaccine, which uses RNA-based adjuvants, has demonstrated efficacy in non-human primates and is now being developed as a prophylactic for COVID-19.
A molecule called microRNA-744, which influences inflammation, has been revealed by researchers as a new drug target for Sjögren's Syndrome.
A group of researchers has used cryo-EM to discover the structure of the remdesivir-bound RNA complex of SARS-CoV-2 and explain how the drug inhibits COVID-19 viral replication.
A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
The visualisation platform is being used to analyse how the SARS-CoV-2 virus causing COVID-19 is evolving and could be used to inform drug design.
According to a new study, the drug remdesivir is a very potent inhibitor for coronavirus polymerases - demonstrating its potential for combatting COVID-19.
Two companies, Neurimmune and Ethris, will leverage their technologies to research, develop and produce an inhaled therapy for COVID-19.
A study has demonstrated that the anti-parasitic drug ivermectin may be effective against SARS-CoV-2, the virus which causes COVID-19.
No tumour prevails on its own. Rather, every tumour needs a community to thrive.
The developers of an RNA imaging technology are using it to create a COVID-19 coronavirus testing kit, able to recognise the viral genome.